In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H dive into Hims & Hers Health's Q3 earnings report. With a record-breaking number of subscribers now exceeding 2 million and significant financial metrics that outperformed estimates, the team dissects key data points and discusses the company's strategic direction. Topics include the rise of personalized solutions among subscribers, the impact of GLP-1 adoption, and the anticipated launch of liraglutide. The episode also touches on potential meal replacements, stock buybacks, financial health indicators, and the ongoing evolution of Hims' multi-product platform.

00:00 Introduction and Q3 Earnings Overview

00:22 Key Metrics and Achievements

01:25 High-Level Reactions and Insights

05:14 Analysis of GLP-1s and Liraglutide

09:05 Personalized Medicine Record Numbers

13:27 Financial Metrics and Shareholder Insights

18:06 North Star Metrics

23:09 Weight Loss Products and Market Impact

33:00 Speculations and Future Products

41:23 Final Thoughts

Website: https://himshouse.substack.com

Twitter/X: @himshouse

Discord: https://discord.gg/tJqGgVhkEt

Jonathan Stern - @jonathanrstern

Louis Stevens - @LA_stevens_

Dr. H - @stayathomedoc

Get full access to Hims House at himshouse.substack.com/subscribe